CareDx (CDNA) Announces $50 Million Stock Repurchase Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
CareDx Announces $50 Million Stock Repurchase Program
December 6, 2022 8:01 AM ESTBRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers today announced that its Board of Directors has authorized a common stock repurchase program of up to $50 million of shares over a period of up to 24 months.
Under the repurchase program, CareDx may purchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions or other means, including through Rule 10b5-1... More
